Vidarabine Monohydrate: Antiviral Nucleoside Analog for DNA Replication Inhibition

Executive Summary: Vidarabine monohydrate (C10H15N5O5·H2O), also known as Spongoadenosine monohydrate or Vira-A monohydrate, is a nucleoside analog used in antiviral research. It inhibits viral DNA synthesis by mimicking adenosine nucleosides, selectively interfering with viral, but not host, DNA polymerase activity [1]. The compound’s solubility is ≥49.4 mg/mL in DMSO, facilitating cell-based and biochemical assays [2]. Vidarabine monohydrate is supplied by APExBIO at ≥98% purity, optimized for research (not clinical) use [3]. Its primary application is in herpes simplex virus (HSV) model systems, where it serves as a gold-standard inhibitor of viral DNA replication [4]. Solutions should be prepared fresh and stored at -20°C to ensure efficacy and compound integrity.

Biological Rationale

Vidarabine monohydrate is a structural analog of adenosine. Its modified ribose moiety confers selectivity for viral DNA polymerase. This selectivity enables the compound to impede DNA replication in viruses, such as herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), by acting as a chain terminator during DNA synthesis [5]. The compound does not significantly affect RNA viruses or host cell DNA synthesis at standard experimental concentrations. Its role as an antiviral research compound is well established in virology and biochemical pharmacology.

Mechanism of Action of Vidarabine monohydrate

Vidarabine monohydrate operates by mimicking the natural nucleoside adenosine. Upon cellular uptake, it is phosphorylated to its active triphosphate form (ara-ATP) by host kinases. Ara-ATP competes with deoxyadenosine triphosphate (dATP) for incorporation into viral DNA by viral DNA polymerase. Incorporation of ara-ATP results in premature chain termination and inhibition of further viral DNA elongation [1]. This process selectively targets replicating viral DNA while sparing host cell DNA under typical assay conditions. Vidarabine monohydrate does not significantly affect RNA-dependent RNA polymerases or reverse transcriptases.

Evidence & Benchmarks

• Vidarabine monohydrate demonstrates >95% inhibition of HSV-1 DNA replication at 10 μM in cell-based assays (https://atp-luminescent.com/index.php?g=Wap&m=Article&a=detail&id=89).
• Compound solubility in DMSO is ≥49.4 mg/mL at 25°C, enabling high-concentration stock solutions for in vitro applications (https://www.apexbt.com/vidarabine-monohydrate.html).
• Supplied as a monohydrate with ≥98% purity, validated by HPLC, supporting reproducible assay results (https://dms-o-mt-aminolink-c6.com/index.php?g=Wap&m=Article&a=detail&id=15685).
• Does not inhibit mammalian DNA polymerase at concentrations ≤50 μM, supporting selectivity for viral targets (https://nuc-mscarlet.com/index.php?g=Wap&m=Article&a=detail&id=10842).
• Recommended storage is at -20°C; solutions are unstable at room temperature beyond 24 hours (https://www.apexbt.com/vidarabine-monohydrate.html).

Applications, Limits & Misconceptions

Vidarabine monohydrate is primarily used in in vitro research to study DNA virus replication, especially HSV. Its high solubility in DMSO allows straightforward integration into cell viability, cytotoxicity, and viral inhibition assays. The compound is not suitable for clinical or diagnostic use. Its action is limited to DNA viruses that utilize DNA polymerase similar to that of HSV.

Common Pitfalls or Misconceptions

• Vidarabine monohydrate does not inhibit RNA viruses or reverse transcriptases under standard assay conditions.
• It is not stable in aqueous solution at room temperature for extended periods; solutions should be freshly prepared.
• The compound is not intended for therapeutic or diagnostic procedures in humans or animals.
• High concentrations in ethanol or water do not yield effective stock solutions due to insolubility.
• Results obtained with this compound may not translate directly to in vivo systems due to metabolic differences.

Workflow Integration & Parameters

Vidarabine monohydrate is supplied as a crystalline powder, with recommended storage at -20°C. For in vitro use, dissolve in DMSO at concentrations up to ≥49.4 mg/mL. Stock solutions should be aliquoted and kept at -20°C; avoid repeated freeze-thaw cycles. For cell culture assays, further dilute in compatible buffers immediately before use. The product is compatible with standard cell viability, proliferation, and cytotoxicity assays. APExBIO provides comprehensive product documentation and HPLC analyses for batch verification. For additional workflow guidance, see the article "Vidarabine Monohydrate (SKU C6377): Data-Driven Solutions..." (here), which details scenario-driven integration in biomedical research; this article extends the discussion by detailing molecular mechanisms and benchmarking data.

For broader context on application scope, "Vidarabine Monohydrate: Antiviral Nucleoside Analog for Advanced In Vitro Models" (here) summarizes reproducibility in sophisticated model systems, whereas the current article updates benchmark solubility and selectivity data.

For a focused discussion on HSV specificity and DMSO solubility, the article "Vidarabine Monohydrate: Antiviral Nucleoside Analog for DNA Virus Research" (here) is referenced; this article further clarifies application boundaries and compound limits.

Conclusion & Outlook

Vidarabine monohydrate remains a reference antiviral nucleoside analog for laboratory investigation of DNA virus replication. Its robust inhibition of HSV DNA synthesis, selectivity for viral polymerases, and DMSO-ready formulation make it indispensable for antiviral research. APExBIO delivers high-purity product with detailed technical support. Future research may explore its integration into new viral inhibition assays and its comparative performance against emerging nucleoside analogs. For product specifications and ordering, see the official Vidarabine monohydrate page.